| Identification | Back Directory | [Name]
L-Proline, L-alanyl-3-[[1-oxo-6-(trimethylammonio)hexyl]amino]-D-alanyl-3-[[(2-hydroxyacetyl)amino]methyl]-L-phenylalanyl-1-[6-[[[4-(2-aminoethyl)phenyl]methyl](3-carboxy-1-oxopropyl)amino]hexyl]-5-fluoro-L-tryptophyl-(3S)-3-hydroxy-L-prolyl-L-threonyl-O-methyl-L-tyrosyl-2-methyl-, (4→1),(8→4)-dilac… | [CAS]
2407527-16-4 | [Synonyms]
Enlicitide chloride | [Molecular Formula]
C82H110FN14O15.Cl | [MOL File]
2407527-16-4.mol | [Molecular Weight]
1586.29 |
| Chemical Properties | Back Directory | [form ]
Solid | [color ]
White to off-white | [Sequence]
Ala-{Dpr}-Phe-Trp-Pro-Thr-Tyr-Pro(Covalent bridge:Phe3-Pro5,Ala1-Trp4,Trp4-Pro8,Ala1-Pro8,D-Dpr2) |
| Hazard Information | Back Directory | [Uses]
Enlicitide chloride is an orally active inhibitor for PCSK9 that blocks the interaction between LPL receptor and PSCK9, with an IC50 of 2.5 nM. Enlicitide chloride can be used in the study of cardiovascular diseases such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome or related cardiovascular and cardiometabolic disorders[1][2][3]. | [References]
[1] Ding FX, et al. Preparation of cyclic peptides as PCSK9 antagonist compounds: World Intellectual Property Organization, WO2019246349. 2019-12-26.
[2] WHO Drug Information-World Health Organization (WHO).
[3] Ahamad S, et al., Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. J Med Chem. 2022 Dec 8;65(23):15513-15539. DOI:10.1021/acs.jmedchem.2c01290 |
|
|